Taysha Gene Therapies, Inc. TSHA Change in Deferred Revenue
Change in Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInContractWithCustomerLiability.
The official record: Taysha Gene Therapies, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →
Ask your AI about Taysha Gene Therapies, Inc.'s change in deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Taysha Gene Therapies, Inc.'s change in deferred revenue?
- Taysha Gene Therapies, Inc. (TSHA) reported change in deferred revenue of -$5.49M in Q4 2025.
- How has Taysha Gene Therapies, Inc.'s change in deferred revenue changed year-over-year?
- Taysha Gene Therapies, Inc.'s change in deferred revenue decreased by 171.3% year-over-year, from -$2.02M to -$5.49M.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s change in deferred revenue?
- Over 3 years (2022 to 2025), Taysha Gene Therapies, Inc.'s change in deferred revenue has grown at a -33.7% compound annual growth rate (CAGR), from $33.56M to -$9.77M.
- What does change in deferred revenue mean?
- Change in payments received from customers for goods/services not yet delivered — a key SaaS and subscription metric.